Aprea Therapeutics (NASDAQ: APRE)

“This transformational financing is a significant commitment by top-tier biotech investors who believe in the potential of APR1-1051 to impact the lives of cancer patients,” said Oren Gilad, Ph.D., President and CEO of Aprea. Read more: bit.ly/4m5Ho0i $APRE

Aprea announced the closing of its previously announced oversubscribed $30M private placement. Funding will support the ongoing development of APR-1051, including expansion into selected patient populations where the WEE1 mechanism is well suited. bit.ly/4m5Ho0i $APRE

Aprea highlighted positive emerging clinical activity for APR-1051, a potent and selective WEE1 kinase inhibitor, with a confirmed partial response in the ongoing Phase 1 ACESOT-1051 trial. A further update from the trial is expected in the second quarter of 2026. Learn more: bit.ly/3NWHgmZ $APRE

Eugene Kennedy, MD, Chief Medical Advisor at Aprea, comments on the confirmed partial response observed in the 220 mg cohort of the ongoing Phase 1 ACESOT-1051, indicating anti-tumor activity of APR-1051 in biomarker-defined cancers. Learn more: bit.ly/3NWHgmZ $APRE

Aprea today announced the confirmation of a partial response (PR) in its ongoing ACESOT-1051 trial evaluating APR-1051, a potent and selective WEE1 kinase inhibitor. This patient achieved a 50% reduction in target lesion size at first scan, with an additional 9.5% reduction in target lesion size, as well as a reduction in CA-125 levels. Read more: bit.ly/3NWHgmZ $APRE

Aprea is well-positioned to execute on key development milestones, with capital in place to support upcoming milestones, including additional enrollment of patients at key dose levels in ongoing ACESOT-1051 trial. Read more from our corporate update: bit.ly/47B9z0V $APRE

Aprea's clinical team was strengthened with the appointment of Eugene (Gene) Kennedy, MD, as Chief Medical Advisor to support next phase of clinical development. Read more on Aprea's clinical progress and potential upcoming key milestones: bit.ly/47B9z0V $APRE

Aprea's WEE1 inhibitor APR-1051 achieved early clinical proof-of-concept in the ongoing ACESOT-1051 trial with two partial responders at first scan in endometrial cancer patients with PPP2R1A mutation. Read more from Aprea's corporate update: bit.ly/47B9z0V $APRE

“We enter 2026 with strong momentum following a year of meaningful execution across our portfolio,” said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea. Read more on Aprea's potential upcoming key milestones: bit.ly/47B9z0V $APRE

Aprea today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update. For key business updates and potential upcoming key milestones: bit.ly/47B9z0V $APRE

Tomorrow, February 26th, at 8:40 am EST, Aprea President and CEO Oren Gilad, Ph.D., will provide a corporate update at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. Join the webcast here: bit.ly/4rNl5hw $APRE

A second unconfirmed partial response has been observed in ongoing ACESOT-1051 trial evaluating WEE1 inhibitor APR-1051. At the 220 mg dose level, 50% tumor shrinkage was demonstrated and significant biomarker reduction, with only Grade 1 adverse events. bit.ly/3ONy4Bn $APRE

Emerging clinical proof of concept responses in the ongoing Ph.1 ACESOT-1051 trial evaluating APR-1051, without class-limiting toxicity to date, support Aprea’s development strategy of differentiated WEE1 inhibition with an improved therapeutic index. bit.ly/3ONy4Bn $APRE

Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea, comments on the observation of 50% tumor shrinkage and significant CA-125 biomarker reduction observed at 220 mg dose level in the ongoing Phase 1 ACESOT-1051 trial: bit.ly/3ONy4Bn $APRE

Eugene Kennedy, MD, Chief Medical Advisor at Aprea, comments on the second partial response observed in the ongoing Phase 1 ACESOT-1051 trial evaluating the Company's investigational WEE1 kinase inhibitor APR-1051: bit.ly/3ONy4Bn $APRE

Aprea Therapeutics today announced additional positive preliminary data from the ongoing Phase 1 ACESOT-1051 trial evaluating its investigational WEE1 kinase inhibitor APR-1051. Read more: bit.ly/3ONy4Bn $APRE

Aprea today announced that Oren Gilad, Ph.D., President and CEO, will provide a corporate update at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, on Thursday, February 26th. For details and registration: bit.ly/4rNl5hw $APRE

Broad intellectual property protection and ongoing clinical progress position Aprea for long-term value creation, with core patent families expected to provide exclusivity into 2045. Read more about our expanded global IP estate: bit.ly/4rEYXpw $APRE

Lead WEE1 inhibitor candidate APR-1051 is advancing in Ph.1 trials, with early clinical PoC demonstrated and multiple meaningful 2026 data readouts anticipated. Read more on our strengthened global patent portfolio supporting our DDR-focused oncology pipeline: bit.ly/4rEYXpw $APRE

Read full comments from Oren Gilad, Ph.D., President and Chief Executive Officer, on the expansion of Aprea's intellectual property estate, bolstering global IP coverage for the Company's WEE1 and ATR programs: bit.ly/4rEYXpw $APRE